The research, whose first authors include Mohammed Inayatullah and Engin Demirdizen, integrated an unusually broad array of data modalities to address a question that has lingered in the field: whether conserved molecular programs underpin therapy resistance regardless of cancer type. The team combined single-cell RNA sequencing, spatial transcriptomics, regulatory network modeling, transcription factor binding data, and pharmacologic perturbation experiments. By layering these approaches across several cancer types, they were able to define what they describe as a pan-cancer, proliferative chemoresistant tumor state—a shared cellular identity that resistant cells from different organs appear to converge upon under the selective pressure of chemotherapy.

The technical findings are striking in their departure from expectation. Rather than exhibiting the low proliferative activity associated with quiescence, resistant tumor cells in the study displayed elevated G2/M and S-phase cell cycle signatures, indicating that they were actively progressing through DNA replication and mitosis at the time of or following treatment. Gene set analyses revealed enriched expression of E2F and MYC target genes, two transcriptional programs classically associated with driving cell cycle entry and growth. Alongside these, the resistant cells showed activation of DNA repair pathways, consistent with an enhanced capacity to mend the damage inflicted by genotoxic chemotherapy, and of PI3K/AKT signaling, a pro-survival axis that supports metabolism and continued proliferation even under stress.

Central to this resistant state, the researchers identified the transcription factor MYC as its master regulator. MYC, one of the most frequently dysregulated oncogenes in human cancer, showed progressive activation along the resistance trajectory—in other words, as cells moved toward a chemoresistant phenotype, MYC activity climbed steadily. Spatial transcriptomics added a clinically meaningful dimension: MYC expression was concentrated in focal pockets within resistant epithelial niches, suggesting that resistant cells do not emerge randomly throughout a tumor but cluster in specific microenvironments where the MYC-driven program is sustained. This spatial organization may explain why resistant clones can dominate recurrences so rapidly once first-line therapy fails.

Perhaps the most consequential discovery from the study concerns a previously underappreciated MYC target gene: SRM, which encodes spermidine synthase, an enzyme central to the biosynthesis of polyamines. The team found that SRM acts as a conserved effector of chemoresistance, promoting polyamine production that the resistant cells require for chromatin stability and metabolic resilience. Polyamines—putrescine, spermidine, and spermine—are small, positively charged molecules that bind nucleic acids and support numerous aspects of cell growth, but their specific role in maintaining the chromatin architecture of drug-resistant cells had not been defined in this context. The new data position SRM not merely as a downstream passenger but as a functional pillar of the resistant phenotype.

The clinical implications of the MYC–SRM axis were reinforced by survival analyses. SRM expression in patient tumors correlated with MYC binding at its regulatory regions and predicted poor patient survival, marking the enzyme as a potential biomarker of therapeutic failure as well as a target in its own right. When the authors examined whether this axis was merely correlative, the answer was emphatically no. Functional validation experiments spanning cancer cell lines, patient-derived organoids, and mouse models demonstrated that pharmacologic inhibition of MYC, of SRM, or of WNT signaling restored chemotherapy sensitivity, suppressed resistance-associated pathways, and reactivated apoptosis—the programmed cell death that chemotherapy is designed to trigger but that resistant cells evade.

What makes this work particularly compelling is the convergence of validation across model systems. Cell lines allow precise mechanistic dissection, but they can diverge from human disease. Patient-derived organoids, which retain much of the cellular heterogeneity and drug response of the original tumors, and in vivo mouse models provide stronger translational evidence. Demonstrating that disrupting the MYC–SRM module resensitizes tumors across all three platforms, and that spatial and survival analyses in human tissues confirm the axis’s clinical relevance, argues that this is a druggable vulnerability rather than a laboratory artifact. The authors go so far as to establish the MYC–SRM axis as a tractable module in treatment-refractory cancers, a claim supported by the pharmacologic tools already available against components of the polyamine biosynthesis pathway.

The conceptual reframing is equally significant. If chemoresistance is not principally a matter of cells going dormant but of cells rewiring themselves into an aggressive, MYC-driven proliferative and repair-competent state, then therapeutic strategies must be recalibrated. Approaches that simply target quiescent or mesenchymal phenotypes may miss the dominant biology of resistance. Conversely, combination regimens pairing conventional chemotherapy with inhibitors of MYC activity, spermidine synthase, or WNT signaling could in principle prevent the emergence or persistence of resistant clones by striking at the very engine of their survival. The finding that PI3K/AKT signaling and DNA repair programs are co-activated in the resistant state further suggests additional combination nodes for drug development.

There are, of course, well-known challenges ahead. MYC has long been considered notoriously difficult to drug directly, though indirect strategies—such as targeting MYC-dependent metabolic enzymes like SRM, or exploiting synthetic lethal interactions—have gained traction in recent years. The identification of SRM as a conserved, druggable effector downstream of MYC offers exactly the kind of actionable node that the field has sought: inhibiting a metabolic enzyme is far more tractable pharmacologically than inhibiting a transcription factor. Whether SRM inhibitors can be advanced safely into clinical combination trials, and whether the pan-cancer signature holds uniformly across all epithelial malignancies, will require prospective clinical validation. Nonetheless, the breadth of evidence assembled in this study—from single-cell and spatial genomics to organoids and animal models—makes a strong case that the MYC–SRM axis represents a genuine Achilles’ heel of chemotherapy-resistant tumors.

The study, funded by the Neye Foundation, the Novo Nordisk Foundation, the Danish National Research Foundation, the Danish Cancer Society, and ICURe grants, is among the first comprehensive efforts to redefine chemoresistance at a pan-cancer level using integrated single-cell and spatial technologies. By demonstrating that a single, conserved, MYC-orchestrated proliferative program underlies treatment failure across diverse cancer types, and by pinpointing spermidine synthase as a druggable linchpin of that program, the work offers oncologists a new conceptual map of resistance and a concrete therapeutic entry point. For patients whose tumors have exhausted standard options, the prospect of restoring chemotherapy sensitivity by dismantling this shared molecular machinery is a development worth watching closely in the years ahead.

Subject of Research: Pan-cancer molecular signatures of chemotherapy resistance and the MYC–SRM axis

Article Title: Uncovering pan-cancer signatures of chemoresistance

Article References: Inayatullah, M., Demirdizen, E., Keepers, Z., Correia, C. M., Hashemi, S. M., Tripathi, K., Sadhukhan, S., Bardhan, I., Mariappan, A., Rassool, F. V., Terp, M. G., Shukla, H. D., & Tiwari, V. K. (2026). Uncovering pan-cancer signatures of chemoresistance. Genome Medicine. https://doi.org/10.1186/s13073-026-01763-2

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01763-2

Keywords: chemoresistance, MYC, SRM, spermidine synthase, single-cell RNA sequencing, spatial transcriptomics, pan-cancer, drug resistance, polyamine biosynthesis, E2F, PI3K/AKT signaling, Genome Medicine

ECT2, or epithelial cell transforming sequence 2, has long presented oncologists with a paradox. Across different cancer types it has been reported to behave sometimes as an oncogene that drives tumor growth and sometimes as a tumor suppressor that restrains it, with its effect apparently dictated by a mixture of intrinsic cellular factors and cues from the surrounding tumor microenvironment. What has been missing, the authors argue, is a clear picture of what ECT2 actually does in PTC, where its expression dynamics, clinical relevance and mechanism of action had remained poorly defined. The new work sets out to fill that gap with a combination of patient tissue analysis and mechanistic experiments in cell lines.

The team began by measuring ECT2 in surgical specimens from PTC patients using immunohistochemistry, a technique that reveals where proteins accumulate within tissue sections. They complemented this with quantitative real-time PCR and Western blotting to quantify messenger RNA and protein levels in PTC cell lines compared with normal thyroid epithelial cells. The results were consistent across methods: ECT2 was significantly upregulated in tumor cells, and high expression in patient tumors tracked closely with poor prognosis, marking the protein as a potential predictive biomarker for the disease.

To probe what ECT2 was actually doing, the researchers turned to loss-of-function experiments in two widely used PTC cell lines, TPC-1 and BCPAP. When they knocked down ECT2, the cells’ capacity to proliferate dropped sharply, as measured by CCK-8 assays and colony formation tests, which gauge both short-term metabolic activity and the ability of individual cells to establish expanding colonies. Transwell migration and invasion assays showed that ECT2 depletion also hampered the cells’ movement through artificial barriers, a laboratory proxy for the invasive behavior that makes cancers dangerous. Conversely, activating ECT2 signaling pushed proliferation in the opposite direction, confirming the protein’s role as a growth promoter in these cells.

The mechanistic heart of the study came from RNA sequencing, which allowed the team to survey the entire transcriptomic landscape of PTC cells with and without ECT2. That analysis revealed a dual regulatory scheme. On one side, ECT2 suppresses the lipoic acid pathway; on the other, it activates the PI3K/AKT pathway, a canonical growth-signaling route frequently hijacked in human cancers. Lipoic acid, a mitochondrial cofactor essential for energy-generating enzyme complexes, has emerged in recent years as a regulator of cellular metabolism, and its suppression by ECT2 suggests the protein is actively reshaping how thyroid tumor cells produce and spend energy.

The sequencing data pointed to a specific chain of events downstream of ECT2. The protein induces phosphorylation of RhoA, a small GTP-binding protein involved in cytoskeletal regulation, which in turn activates the transcription factor MYC, one of the most potent drivers of gene expression in proliferating cells. Activated MYC ramps up the expression of glycolysis-related genes, pushing the cells toward the fermentative glucose metabolism that characterizes the Warburg effect, the metabolic reprogramming that allows rapidly dividing tumors to generate biomass and signaling intermediates even in oxygen-rich conditions. In effect, ECT2 appears to rewire PTC cells’ energy economy from the top down, through a signaling cascade that connects a cytoskeletal regulator to one of cancer biology’s most influential transcription factors.

Perhaps the most clinically provocative finding concerns drug resistance. The researchers found that ECT2 downregulates drug influx transporters, the molecular gatekeepers that carry chemotherapeutic agents into cells, while simultaneously upregulating efflux transporters that pump drugs back out. The net effect is that tumor cells take in less medication and expel more of what does get in, raising the IC50 value, the drug concentration required to kill half the cells, and thereby rendering them measurably more resistant to treatment. This transport-based resistance mechanism operates independently of the metabolic reprogramming, giving ECT2 a second, parallel route to worsening patient outcomes.

Taken together, the findings recast ECT2 as a hub where growth signaling, metabolic reprogramming and drug transport converge in papillary thyroid carcinoma. The authors conclude that the protein drives PTC cell proliferation through its dual suppression of the lipoic acid pathway and activation of PI3K/AKT, while its effects on RhoA phosphorylation, MYC activation and glycolysis gene expression provide the metabolic fuel for unchecked growth, and its manipulation of transporters undermines chemotherapy. They emphasize that these discoveries offer a novel entry point for targeting the ECT2 signaling axis therapeutically, potentially combining metabolic interventions with strategies to restore drug sensitivity.

The study, supported by the Wuxi Double Hundred Top-notch Talent Program, also carries important caveats that the authors themselves acknowledge. The core mechanistic work was performed in cell lines, and while the clinical correlation between ECT2 expression and prognosis was established in patient specimens, the full pathway from protein to patient outcome will require further validation in animal models and larger clinical cohorts. The researchers call explicitly for continued mechanistic and translational investigation, noting that turning a biomarker discovery into a therapeutic strategy is a long road involving drug development, delivery optimization and careful patient stratification.

For a cancer that is often described as highly curable, papillary thyroid carcinoma nonetheless poses real challenges in the subset of patients with aggressive, treatment-refractory disease, and the identification of ECT2 as a driver of both proliferation and chemoresistance offers a molecular handle on that problem. If subsequent studies confirm that blocking ECT2 activity, or restoring lipoic acid pathway function, can sensitize tumors to existing drugs, the protein could become both a prognostic marker guiding treatment intensity and a target for combination therapies aimed at the metabolic vulnerabilities of hard-to-treat thyroid cancers.

Subject of Research: The role of ECT2 in regulating energy metabolism and chemoresistance in papillary thyroid carcinoma.

Article Title: ECT2 antagonizes lipoic acid to modulate papillary thyroid carcinoma progression through energy metabolism pathways

Article References: Huang, Z., Gao, Y., Wang, N., Cai, D., & Bai, N. (2026). ECT2 antagonizes lipoic acid to modulate papillary thyroid carcinoma progression through energy metabolism pathways. Cancer Cell International. https://doi.org/10.1186/s12935-026-04459-0

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04459-0

Keywords: ECT2, papillary thyroid carcinoma, lipoic acid, PI3K/AKT pathway, glycolysis, MYC, RhoA, chemoresistance, cancer metabolism, thyroid cancer, drug transporters, biomarker